Parkinsonian syndromes. Treatment by association of L-dopa plus decarboxylase inhibitor.
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001794:Blood Pressure / Q000187:drug effects; D003653:Decarboxylation; D003863:Depression / Q000139:chemically induced; D003864:Depression, Chemical; D004063:Digestion / Q000187:drug effects; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004296:Dopa Decarboxylase / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006212:Hallucinations / Q000139:chemically induced; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced; D010302:Parkinson Disease, Secondary / Q000188:drug therapy* / Q000209:etiology; D013268:Stimulation, Chemical
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D004338:Drug Combinations; D004295:Dihydroxyphenylalanine; D004296:Dopa Decarboxylase